Potential of human induced pluripotent stem cells in studies of liver disease
Open accessAbstract
Liver disease is a leading cause of death in the Western world. However, our insight into the underlying disease mechanisms and the development of novel therapeutic agents has been hindered by limited availability of primary tissue, intraspecies variability associated with the use of animal models, and reduced long-term viability of isolated and diseased liver cells. The emergence of human induced pluripotent stem cells and differentiation protocols to generate hepatocyte-like cells has opened the possibility of addressing these issues. Here, we discuss the recent progress and potential in the production of various cell types constituting the liver and their applications to model liver diseases and test drug toxicity in vitro.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The repopulation efficiency of HLCs is around 2%, far lower than that of PHHs, which is around 70%.
“The repopulation efficiency of HLCs, which is around 2%, is far lower than that of PHHs, which is around 70% (Ji et al., 2013; Rezvani et al., 2016; Sampaziotis et al., 2015”
From In Vitro Expansion of Primary Human Hepatocytes with Efficient Liver Repopulation Capacity (2018) · cites this paper as Sampaziotis et al., 2015
Section 22 says HLCs have a limited capacity to repopulate the liver in animal models, supporting the general point that their repopulation is limited. It does not give the claimed efficiencies of around 2% for HLCs or 70% for primary human hepatocytes (PHHs), or quantify the comparison between them. (LLM, conf=0.86)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 61 · Cited by 49
Research works printed but not linked: 10
- Horton R. GBD 2010: understanding disease, injury, and risk. Lancet. 2 2012;380:2053-4.
- Gerbal-Chaloin S, Funakoshi N, Caillaud A, Gondeau C, Champon B, Si- 19 Tayeb K. Human induced pluripotent stem cells in hepatology: beyond the 20 proof of concept. Am J Pathol. 2014;184:332-47
- Sancho-Bru P, Najimi M, Caruso M, Pauwelyn K, Cantz T, Forbes S, et al. 22 Stem and progenitor cells for liver repopulation: can we standardise the 23 process from bench to bedside? Gut. 2009;58:594-603. 21 Pediatr. 2002;161:S20-S34.
- Roberts EA, Schilsky ML; AASLD. Diagnosis and treatment of Wilson 2 disease: an update. Hepatology. 2008;47:2089-111.
- Zhang S, Chen S, Li W, Guo X, Zhao P, Xu J, et al. Rescue of ATP7B 4 function in hepatocyte-like cells from Wilson's disease induced pluripotent 5 stem cells using gene therapy or the chaperone drug curcumin. Hum Mol 6 Genet. 2011;20:3176-87.
- Yi F, Qu J, Li M, Suzuki K, Kim NY, Liu GH, et al. Establishment of hepatic 8 and neural differentiation platforms of Wilson's disease specific induced 9 pluripotent stem cells. Protein Cell. 2012;3:855-63.
- Rader DJ, Cohen J, Hobbs HH. Monogenic hypercholesterolemia: new 11 insights in pathogenesis and treatment. J Clin Invest. 2003;111:1795-803.
- Cayo MA, Cai J, Delaforest A, Noto FK, Nagaoka M, Clark BS, et al. JD 13 induced pluripotent stem cell-derived hepatocytes faithfully recapitulate the 14 pathophysiology of familial hypercholesterolemia. Hepatology. 2012;56:2163- 15 2171.
- Voora D, Shah SH, Reed CR, Zhai J, Crosslin DR, Messer C, et al. 17 Pharmacogenetic predictors of statinmediated low-density lipoprotein 18 cholesterol reduction and dose response. Circ Cardiovasc Genet. 19 2008;1:100-106.
- European Association for Study of Liver. EASL Clinical Practice Guidelines: 21 management of hepatitis C virus infection. J Hepatol. 2014;60:392-420.
- Authors
- Sampaziotis, F., Segeritz, C., & Vallier, L.
- Affiliations
- Wellcome/MRC Cambridge Stem Cell Institute (GB)
- Corresponding author
- Vallier, Ludovic
- Venue
- Hepatology
- Published
- 2015-02-10
- Volume
- 62
- Issue
- 1
- Pages
- 303-311
- ISSN
- 0270-9139 (ISSN-L)
- 1527-3350
- OpenAlex
- W1879322546
- Cited by
- 49
- References
- 61
- Citations by year
- 2026: 1 · 2025: 5 · 2024: 1 · 2023: 3 · 2022: 6 · 2021: 5 · 2020: 2 · 2019: 3 · 2018: 5 · 2017: 7 · 2016: 9 · 2015: 2
- FWCI
- 0.56
- Type
- journal article
- Language
- en
- Open access
- Licence
- Locations
- Hepatology (publishedVersion)
- PubMed (publishedVersion)
- Apollo (University of Cambridge) (submittedVersion)
- Funders
- Medical Research Council
- European Research Council
- European Commission
- Children Disease Liver Fundation
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Keywords
- human induced pluripotent stem cells, liver disease modeling, hepatocyte-like cells, liver cell differentiation, drug toxicity testing, in vitro disease model, liver cell types, animal model limitations
- MeSH terms
- Humans, Liver Diseases, Hepatocytes, Chemical and Drug Induced Liver Injury, Induced Pluripotent Stem Cells, Proteostasis Deficiencies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
